N-Acetyl Cystein and Contrast Nephropathy

• Status: Unknown status
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: All

Summary

There are many controversies about the role of N-Acetyl Cystein in preventing of contrast nephropathy. These contradictory results may be due to different criteria for patients' selection, different end points, different type and dose of N-Acetyl Cystein administration and finally different prophylactic measures other than N-Acetyl Cystein. The investigators try to enroll a double blind double dummy study with a good power to compare the effect of this drug both in the form of oral and intravenous against the placebo in preventing the contrast nephropathy in the patients whom undergo coronary angiography/angioplasty.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imam Khomeini Hospital
• Collaborator: Tehran Heart Center

Criteria

Inclusion Criteria:

• Age more than 18

• chronic Kidney disease stage 2-4

• use of nephrotoxins in last week leading to angiography

Exclusion Criteria:

• Acute kidney injury

• concomitant use of other nephrotoxins

• need of repeated imaging with contrast in five days after the first surgery

• need for surgery in next five day after the contrast exposure

• need of using nephrotoxins in next five days after contrast exposure